Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemoglobin subunit gamma-2 is a globin protein encoded by the HBG2 gene and forms part of fetal hemoglobin (HbF), comprising two alpha and two gamma chains. This subunit predominates at birth and is essential for oxygen transport in fetal development, with expression normally silenced postnatally. Persistent or reactivated HBG2 expression can ameliorate clinical severity in hemoglobinopathies such as sickle cell disease and beta-thalassemia. Genetic variations in the HBG2 promoter and regulatory pathways control its expression, making HBG2 a major therapeutic target for pharmacologic and gene editing strategies seeking to increase HbF in affected patients
Activation of HBG2 promoter to induce HbF synthesis (by hydroxyurea, decitabine, butyrate derivatives) Epigenetic modulation of transcriptional regulators/repressor complexes (e.g., BCL11A, NuRD)
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemoglobin subunit gamma-2 (HBG2).